Breaking News
Get 45% Off 0
🎯 Trump Tariffs Hit Markets: Here's What Smart Investors Should Consider
Recession-Resistant Stocks

Amgen (AMGN) Unveils Auto Injector Device For Enbrel In US

By Zacks Investment ResearchStock MarketsNov 19, 2017 09:30PM ET
www.investing.com/analysis/amgen-amgn-unveils-auto-injector-device-for-enbrel-in-us-200266718
Amgen (AMGN) Unveils Auto Injector Device For Enbrel In US
By Zacks Investment Research   |  Nov 19, 2017 09:30PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
AMZN
+2.76%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AMGN
+1.97%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PFE
+0.70%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
NVS
+0.92%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ABBV
+2.03%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Amgen, Inc. (NASDAQ:AMGN) announced the launch of its Enbrel Mini with AutoTouch, a new auto injector device for Enbrel in the United States.

The Enbrel Mini single-dose prefilled cartridges, used with the AutoTouch reusable autoinjector device, provide an additional administration option for rheumatoid arthritis drug Enbrel. The Enbrel Mini with AutoTouch device was approved by the FDA in September.

Amgen’s shares have rallied 16.2% this year so far, better than the industry’s growth of 1.5%.

Sales of Amgen’s largest product Enbrel have been soft for quite some time now. Pricing pressure and stiff competition are hurting sales of Enbrel, one of the main drivers of Amgen’s revenues. Enbrel has recorded sales of $4.01 billion in 2017 so far, a decline of 7% year over year.

The RA market is extremity crowded, given the presence of treatments like AbbVie’s (NYSE:ABBV) Humira and Pfizer’s (NYSE:PFE) Xeljanz among others.

It remains to be seen if this new device for Enbrel can lead to some improvement in sales. However, on the Q3 conference call, Amgen had said that the declining trends in price and market share will continue in 2018.

In Europe, while biosimilar versions of Enbrel are available, in the United States, Sandoz, the generic arm of Novartis (NYSE:NVS) , has received FDA approval for its biosimilar version of Enbrel, Erelzi. Notably, Erelzi is yet to be launched in the United States.

Currently, Amgen has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Wall Street’s Next Amazon (NASDAQ:AMZN)

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>



Pfizer, Inc. (PFE): Free Stock Analysis Report

Novartis AG (NVS): Free Stock Analysis Report

AbbVie Inc. (ABBV): Free Stock Analysis Report

Amgen Inc. (AMGN): Free Stock Analysis Report

Original post

Amgen (AMGN) Unveils Auto Injector Device For Enbrel In US
 

Related Articles

Amgen (AMGN) Unveils Auto Injector Device For Enbrel In US

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email